- Home
- CUE vs ADAG Comparison
CUE vs ADAG Comparison
Compare CUE & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- ADAG
- Stock Information
- Founded
- CUE 2014
- ADAG 2011
- Country
- CUE United States
- ADAG China
- Employees
- CUE N/A
- ADAG N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- ADAG Health Care
- Exchange
- CUE Nasdaq
- ADAG Nasdaq
- Market Cap
- CUE 61.1M
- ADAG 84.4M
- IPO Year
- CUE 2018
- ADAG 2021
- Fundamental
- Price
- CUE $0.70
- ADAG $1.61
- Analyst Decision
- CUE Strong Buy
- ADAG Strong Buy
- Analyst Count
- CUE 2
- ADAG 3
- Target Price
- CUE $3.00
- ADAG $7.67
- AVG Volume (30 Days)
- CUE 215.8K
- ADAG 53.4K
- Earning Date
- CUE 11-12-2025
- ADAG 08-12-2025
- Dividend Yield
- CUE N/A
- ADAG N/A
- EPS Growth
- CUE N/A
- ADAG N/A
- EPS
- CUE N/A
- ADAG N/A
- Revenue
- CUE $8,286,000.00
- ADAG $103,204.00
- Revenue This Year
- CUE N/A
- ADAG $7,411.34
- Revenue Next Year
- CUE N/A
- ADAG $28.29
- P/E Ratio
- CUE N/A
- ADAG N/A
- Revenue Growth
- CUE N/A
- ADAG N/A
- 52 Week Low
- CUE $0.54
- ADAG $1.33
- 52 Week High
- CUE $1.99
- ADAG $3.16
- Technical
- Relative Strength Index (RSI)
- CUE 40.92
- ADAG 38.71
- Support Level
- CUE $0.68
- ADAG $1.47
- Resistance Level
- CUE $0.85
- ADAG $1.93
- Average True Range (ATR)
- CUE 0.07
- ADAG 0.14
- MACD
- CUE -0.01
- ADAG -0.02
- Stochastic Oscillator
- CUE 5.83
- ADAG 29.17
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.